An AI-powered platform which is expanding globally through its ability to detect and monitor cognitive impairment has showed its efficacy in Multiple Sclerosis (MS) patients through a new study.
The CognICA platform has seen adoption in territories including the United States, UAE and in both NHS and private healthcare in the UK, on the strength of its ability to detect pre-dementia symptoms more quickly and cost-effectively than ever before.
The integrated cognitive assessment (ICA) technology, developed by Cognetivity Neurosciences, is now set to help support MS patients after its potential was shown through a new study, with Cognetivity hailing its potential to “bring about a new paradigm in monitoring the progression and treatment of MS in clinical care”.
The research investigated the link between performance of people with MS through the ICA test, the technology that drives Cognetivity’s CognICATM clinical cognitive assessment tool, and brain imaging markers of the disease.
The effects of changes in brain volume – in particular deep grey matter – in patients with early relapse-remitting MS (RRMS) were related to brain performance in the form of information processing speed, as measured using CognICA.
The results showed that compared to healthy subjects, people with RRMS had lower accuracy in the ICA test and higher amounts of thalamic atrophy (loss of brain volume).
This means that CognICA is capable of detecting lowered brain volume and predicting the extent of disease-related damage without having to use more invasive and expensive techniques.
These results further demonstrate the advantage of the CognICA platform in providing accurate and repeatable measures of cognition in MS, a disease which affects around 130,000 people in the UK – with 7,000 new cases each year – and around one million people in the US.
Earlier detection at scale allows for more effective treatment and better patient outcomes.
CognICA’s use of machine learning algorithms and artificial intelligence also allows the continuous monitoring and improvement of clinical decision making, leading to more personalised healthcare.
“Brain health is the biggest healthcare challenge of our time. We are extremely excited to see the impact that CognICA can have on the lives of people living with MS and other brain health issues,” said Dr Sina Habibi, CEO of Cognetivity.
“CognICA, with its unique characteristics of being able to detect the earliest signs and progression of such disorders will play a hugely important role in tackling this public health crisis.
“By using CognICA, we have the potential to bring about a new paradigm in monitoring the progression and treatment of MS in clinical care.”
